Skip to content
drillr.ai
Sign up

INO

INOVIO PHARMACEUTICALS, INC.

NASDAQ · Healthcare · Biotechnology · US

$1.63
−1.81%
Ask drillr

  • Nov 3, 2026, 16:36 UTC

    Inovio Pharmaceuticals, Aquestive Therapeutics, X4 Pharmaceuticals and Jazz Pharmaceuticals saw unusually high options volume.

    Source:

  • Nov 2, 2026, 21:15 UTC

    INOVIO PHARMACEUTICALS, INC. announced that it will release its third-quarter 2026 financial results after the market close on November 10, 2026.

    Source:

  • Nov 2, 2026, 14:39 UTC

    INOVIO PHARMACEUTICALS, INC. shares rose 184.88% to $1.72 in U.S. trading.

    Source:

  • Nov 2, 2026, 13:22 UTC

    INOVIO PHARMACEUTICALS, INC. shares rose 261.89% to $2.18 in after-hours trading.

    Source:

  • Nov 2, 2026, 13:22 UTC

    The U.S. Food and Drug Administration granted accelerated approval to INOVIO PHARMACEUTICALS, INC.’ immunotherapy drug Veselic for adults with recurrent respiratory papillomatosis, making it the first plasmid DNA-based immunotherapy approved in the United States.

    Source:

  • Nov 2, 2026, 09:29 UTC

    INOVIO PHARMACEUTICALS, INC. shares rose more than 230% in premarket trading.

    Source:

  • Oct 30, 2026, 22:01 UTC

    The U.S. Food and Drug Administration granted accelerated approval to INOVIO PHARMACEUTICALS, INC.’s VOCERYQ for reducing the frequency of surgery in adults with recurrent respiratory papillomatosis.

    Source:

  • Oct 20, 2026, 20:05 UTC

    INOVIO Pharmaceuticals announced that it secured a favorable judgment of $80,416,101 on all claims it filed against VGXI and GeneOne Life Science.

    Source:

  • Aug 25, 2026, 01:56 UTC

    Inovio Pharmaceuticals reported first-half 2026 revenue of 1.137 billion yuan, up 55.5% year-over-year, with net profit attributable to shareholders of 246 million yuan versus a net loss of 30 million yuan in the first half of 2025.

    Source:

  • Aug 13, 2026, 00:04 UTC

    The U.S. Food and Drug Administration completed several key steps in its review of Inovio Pharmaceuticals' biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis.

    Source:

  • Aug 12, 2026, 23:17 UTC

    Inovio Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.

    Source:

  • Jul 29, 2026, 20:01 UTC

    INOVIO Pharmaceuticals announced a proposed public offering of shares of its common stock and accompanying warrants.

    Source: